For your patients who require a fast-acting, easy-to-use acute migraine treatment option that bypasses the stomach
TOSYMRA delivers the efficacy of an injectable in a nasal spray1
The efficacy of TOSYMRA nasal spray is based on relative bioavailability of TOSYMRA compared to a 4-mg Imitrex®
(sumatriptan) subQ injection in healthy adults1
Proportion of patients with migraine relief* by time1
Data from the 4-mg dose arm (n=30) of a sumatriptan subQ dose-ranging, single-attack study (N=242).1
*Migraine relief was defined as the reduction of moderate or severe pain to no or mild pain after dosing without use of rescue medication.1
Sumatriptan injection also has been shown to relieve photophobia, phonophobia, nausea, and vomiting associated with migraine attacks1
An open-label, repeat-dose study assessed the safety and tolerability of TOSYMRA in 167 adult patients diagnosed with episodic migraine with or without aura.2 A post hoc analysis evaluated the change in the number of migraine headache days and hours at month 6 compared to month 1.3
Patients receiving TOSYMRA, who experienced a migraine in both month 1 and 6 (n=105), achieved a statistically significant reduction in mean number of3
In the open-label, repeat-dose study of TOSYMRA, the most common treatment-emergent AEs were application site pain, dysgeusia, application site reaction, upper respiratory tract infection, nasopharyngitis, and sinusitis.2
TOSYMRA is indicated for the acute treatment of migraine with or without aura in adults.
Each patient has a distinct migraine experience
Meet Linda: Can’t find relief
Linda has suffered from migraines for several years; recently, however, the intensity has increased. Prior to this point, Linda had approximately 1 to 2 moderate migraines per week, but the pain associated with these migraines has worsened over time. Linda's migraine attacks can happen at any time, and the typical onset can take approximately 30 to 45 minutes.
Linda tried oral triptans, but she did not experience the relief she needed, especially as the migraines progressed in severity. To try to manage the pain, Linda added nonsteroidal anti-inflammatory drugs (NSAIDs) to her treatment regimen.
Linda has cycled through multiple oral therapies and has yet to find an option that is consistently effective and works fast enough to relieve her migraine attacks. She likes the idea of a fast-acting medication, but has never been comfortable with the idea of self injections.
- A non-oral and non-injectable fast-acting treatment option
- A treatment that Linda can tolerate well
References: 1. TOSYMRA [package insert]. Maple Grove, MN: Upsher-Smith Laboratories, LLC; 2019. 2. Munjal S, Brand-Schieber E, Allenby K, Spierings ELH, Cady RK, Rapoport AM. A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. J Headache Pain. 2017;18(1):31. 3. Halvorsen MB, Zachman MB, Munjal S, Rapoport AM. Evaluation of the Number of Migraine Headache Days and Hours in a Multicenter, Open-Label, Long-Term Safety Study of DFN-02 (Tosymra™; an Intranasal Spray of Sumatriptan 10 mg Plus Permeation Enhancer DDM), for the Acute Treatment of Migraine. Presented at: PAINWeek 2019; September 3-7, 2019; Las Vegas, NV.